MedTrace Logo

CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases

NCT06787560 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-01-22

No results posted yet for this study

Summary

A Clinical Study on the Safety and Effectiveness of CD7 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation for Non-malignant Blood and Immune System Diseases

Conditions

  • Bone Marrow Failure Syndrome

Interventions

BIOLOGICAL

CD7 CAR-T cells injection

Each subject receive CD7 CAR T-cells by intravenous infusion

PROCEDURE

Allo-HSCT

allogeneic hematopoietic stem cell transplantation

Sponsors & Collaborators

  • Yake Biotechnology Ltd.

    collaborator INDUSTRY

  • Zhejiang University

    lead OTHER

Principal Investigators

  • He Huang, MD · Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-31
Primary Completion
2028-01-31
Completion
2028-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06787560 on ClinicalTrials.gov